¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø ¹× °æÀï ºÐ¼®(-2030³â)
Radioligand Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030
»óǰÄÚµå : 1610190
¸®¼­Ä¡»ç : Lucintel
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,774,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,800 £Ü 8,102,000
PDF (2 Users License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 2¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,700 £Ü 9,359,000
PDF (5 Users License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,850 £Ü 12,362,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ ±â¾÷ ³» ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹æ»ç¼º ¸®°£µå ¿ä¹ý µ¿Çâ ¹× Àü¸Á

¼¼°è ¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð°ú Áø´Ü ¼¾ÅÍ ½ÃÀå¿¡¼­ ±âȸ°¡ ÀÖ°í ¹Ì·¡°¡ À¯¸ÁÇÑ ½ÃÀåÀÔ´Ï´Ù. ¼¼°è ¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö 5.0%ÀÇ CAGR·Î 2030³â±îÁö ¾à 138¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº ¾Ï ¹ßº´·üÀÇ Áõ°¡¿Í È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ³ôÀº ¼ö¿äÀÔ´Ï´Ù.

¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀåÀÇ Àü·«Àû ¼ºÀå ±âȸ

¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀåÀº ±â¼ú ¹ßÀü°ú ¾Ï Ä¡·á¿¡¼­ Ç¥Àû Ä¡·áÀÇ ¼ö¿ë È®´ë¿¡ µû¶ó ´Ù¾çÇÑ ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇÏ´Â °ÍÀº »ç¾÷ ¹ßÀü°ú ½ÃÀå È®´ë·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.

Àü¸³¼±¾Ï, ½Å°æ³»ºÐºñÁ¾¾ç, º´¿ë¿ä¹ý, ½ÅÈï½ÃÀå, ÷´Ü ¿µ»ó ÅëÇÕÀº ½ÃÀå ¼ºÀåÀ» À§ÇÑ Àü·«Àû ½ÃÀå ¼ºÀå ±âȸ°¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ´Â ¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀåÀÇ ÀáÀçÀû È®´ë¿Í ±â¼ú °­È­¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀåÀÇ ÃËÁø¿äÀÎ ¹× °úÁ¦

¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀåÀÇ ÁöħÀº ¿©·¯ ±ÔÁ¦, ±â¼ú ¹× °æÁ¦ ÃËÁø¿äÀÎ ¹× °úÁ¦¿¡ ÀÇÇØ Á¤Àǵ˴ϴÙ. ÀÌ·¯ÇÑ ¿äÀÎÀ» ÇØ°áÇÏ´Â °ÍÀÌ ½ÃÀå ¼ºÀå°ú Çõ½Å¿¡ ÇʼöÀûÀÔ´Ï´Ù.

¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀåÀÇ ÃËÁø¿äÀÎ

¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀåÀÇ °úÁ¦

¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀåÀº ±â¼ú ¹ßÀü, ¾Ï ¹ßº´·ü Áõ°¡, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, R&D ÅõÀÚ, ¸ÂÃãÇü ÀÇ·á Æ®·»µå µî¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº °³¹ß ºñ¿ë, ±ÔÁ¦ Àå¾Ö¹°, ½ÃÀå °æÀïÀ» ÇØ°áÇÏ°í ¼ºÀå°ú Çõ½ÅÀ» º¸ÀåÇϱâ À§Çؼ­´Â ³ôÀº °³¹ß ºñ¿ë, ±ÔÁ¦ Àå¾Ö¹°, ½ÃÀå °æÀïÀ» ÇØ°áÇØ¾ß ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ¹æ»ç¼º ¸®°£µå ¿ä¹ý ½ÃÀå : ½ÃÀå ¿ªÇÐ

Á¦3Àå ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼®(2018-2030³â)

Á¦4Àå Áö¿ªº° ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼®(2018-2030³â)

Á¦5Àå °æÀï ºÐ¼®

Á¦6Àå ¼ºÀå ±âȸ¿Í Àü·« ºÐ¼®

Á¦7Àå ÁÖ¿ä ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Radioligand Therapy Trends and Forecast

The future of the global radioligand therapy market looks promising with opportunities in the hospitals & clinics and diagnostic center markets. The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are rising cancer rates and the high demand for effective treatment.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Radioligand Therapy Market

The radioligand therapy market underscores the changes brought about by technology, clinical development, and patient treatment. These trends are transforming the landscape of chemotherapy and broadening the range of indications for radioligand therapies.

The emerging themes of personalized medicine, new frontiers in radiopharmaceutical production, clinical research expansion, incorporation with imaging, and international collaborations are game-changers in the radioligand therapy market. These trends stimulate development, increase efficacy, and elevate the feasibility of targeted cancer treatment options.

Recent Developments in the Radioligand Therapy Market

The recent developments in radioligand therapy, which also include commercialization activities, emphasize technological advancements, clinical application patterns, and marketing trends. These developments create avenues for new research and further descriptive development of radioligand therapy in the management of localized cancer.

In the last one and a half years, advances in FDA approvals, production, clinical trials, incorporation of imaging, and international collaborations have greatly influenced the radioligand therapy market. These advancements foster innovation, improve treatment effectiveness, and increase the potential for commercialization of products, thus defining future targeted cancer therapies.

Strategic Growth Opportunities for Radioligand Therapy Market

The radioligand therapy market presents various opportunities due to technological advancements and the growing acceptance of targeted therapy for cancer treatment. Taking advantage of these opportunities will help in business advancement and market expansion.

There are strategic market growth opportunities in prostate cancer, neuroendocrine tumors, combination therapies, emerging markets, and advanced imaging integration that can be exploited for market growth. These opportunities encourage potential expansion and technology enhancement in the radioligand therapy market.

Radioligand Therapy Market Driver and Challenges

The guiding factors for the radioligand therapy market are defined by several regulatory, technological, and economic drivers and challenges. Addressing these factors is essential for growth and innovation in the marketplace.

Drivers of the Radioligand Therapy Market:

Challenges in the Radioligand Therapy Market:

The radioligand therapy market is driven by technological advancements, increasing cancer prevalence, regulatory approvals, R&D investment, and trends toward personalized medicine. However, high development costs, regulatory hurdles, and market competition must be addressed to ensure growth and innovation.

List of Radioligand Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioligand therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioligand therapy companies profiled in this report include-

Radioligand Therapy by Segment

The study includes a forecast for the global radioligand therapy by isotope, targeted receptor, indication, end use, and region.

Radioligand Therapy Market by Isotope [Analysis by Value from 2018 to 2030]:

Radioligand Therapy Market by Targeted Receptor [Analysis by Value from 2018 to 2030]:

Radioligand Therapy Market by Indication [Analysis by Value from 2018 to 2030]:

Radioligand Therapy Market by End Use [Analysis by Value from 2018 to 2030]:

Radioligand Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

Country Wise Outlook for the Radioligand Therapy Market

Recent developments in the radioligand therapy market include advances in technology, registration, and clinical practice. The growing trend among patients toward personalized medicine and targeted techniques is filling the gap created by recent activity in the field of radioligand therapies in countries like the United States, China, Germany, India, and Japan.

Features of the Global Radioligand Therapy Market

Market Size Estimates: Radioligand therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radioligand therapy market size by various segments, such as by isotope, targeted receptor, indication, end use, and region in terms of value ($B).

Regional Analysis: Radioligand therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different isotope, targeted receptor, indications, end uses, and regions for the radioligand therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioligand therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

Table of Contents

1. Executive Summary

2. Global Radioligand Therapy Market : Market Dynamics

3. Market Trends and Forecast Analysis from 2018 to 2030

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

5. Competitor Analysis

6. Growth Opportunities and Strategic Analysis

7. Company Profiles of Leading Players

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â